Toxicological assessment of chondroitin sulfate oligosaccharide
Archives of Clinical Toxicology · 2023
DOI: 10.46439/toxicology.5.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Toxicology, 2023. Verfasst von Kara D. Lewis und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Toxicology studies were conducted to evaluate the safety of chondroitin sulfate oligosaccharide (CSO) produced by the enzymatic hydrolysis of shark cartilage by a bacterial lyase. Although the safety of chondroitin sulfate, which is used as a dietary supplement, has been investigated, no safety studies have been conducted on CSO. CSO was evaluated in bacterial reverse mutagenesis, mammalian cell gene mutation using mouse lymphoma cells, in vivo mammalian erythrocyte micronucleus assays, and a ninety-day repeated dose oral toxicity study in rats. The study showed that CSO was not genotoxic. The No Observed Adverse Effect Level (NOAEL) was determined to be 4,000 mg/kg bw/day, the highest dose tested.
Zitieren
APA
Lewis, K. D., & Falk, M. (2023). Toxicological assessment of chondroitin sulfate oligosaccharide. Archives of Clinical Toxicology. https://doi.org/10.46439/toxicology.5.023
Vancouver
Lewis KD, Falk M. Toxicological assessment of chondroitin sulfate oligosaccharide. Archives of Clinical Toxicology. 2023. doi:10.46439/toxicology.5.023
BibTeX
@article{Lewis2023,
author = {Lewis, Kara D. and Falk, Michael},
title = {Toxicological assessment of chondroitin sulfate oligosaccharide},
journal = {Archives of Clinical Toxicology},
year = {2023},
doi = {10.46439/toxicology.5.023}
}
EUVIMED